KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor

KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor

Source: 
Fierce Biotech
snippet: 

PARP inhibitors like Lynparza from Merck and AstraZeneca have been effective in some patients with ovarian and breast cancers, but many develop resistance to the drugs, and some people don’t respond at all. KSQ Therapeutics hopes to provide hope for those patients with a first-in-class drug that may be able to boost Lynparza’s effectiveness when used in combination with it—and the company has rolled out promising animal data to back up that strategy.